These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

59 related items for PubMed ID: 7488001

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Interaction of an anti-HIV peptide, T22, with gp120 and CD4.
    Tamamura H, Otaka A, Murakami T, Ishihara T, Ibuka T, Waki M, Matsumoto A, Yamamoto N, Fujii N.
    Biochem Biophys Res Commun; 1996 Feb 15; 219(2):555-9. PubMed ID: 8605026
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Analysis of the interaction of an anti-HIV peptide, T22 ([Tyr5, 12, Lys7]-polyphemusin II), with gp120 and CD4 by surface plasmon resonance.
    Tamamura H, Ishihara T, Otaka A, Murakami T, Ibuka T, Waki M, Matsumoto A, Yamamoto N, Fujii N.
    Biochim Biophys Acta; 1996 Nov 14; 1298(1):37-44. PubMed ID: 8948487
    [Abstract] [Full Text] [Related]

  • 6. Molecular parameters for the anti-human immunodeficiency virus activity of T22 ([Tyr5,12, Lys7]-polyphemusin II).
    Otaka A, Tamamura H, Terakawa Y, Masuda M, Koide T, Murakami T, Nakashima H, Matsuzaki K, Miyajima K, Ibuka T.
    Biol Pharm Bull; 1994 Dec 14; 17(12):1669-72. PubMed ID: 7735216
    [Abstract] [Full Text] [Related]

  • 7. Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes.
    Zhang X, Gaubin M, Briant L, Srikantan V, Murali R, Saragovi U, Weiner D, Devaux C, Autiero M, Piatier-Tonneau D, Greene MI.
    Nat Biotechnol; 1997 Feb 14; 15(2):150-4. PubMed ID: 9035140
    [Abstract] [Full Text] [Related]

  • 8. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
    Delézay O, Hammache D, Fantini J, Yahi N.
    Biochemistry; 1996 Dec 10; 35(49):15663-71. PubMed ID: 8961929
    [Abstract] [Full Text] [Related]

  • 9. An anti-HIV peptide, T22, forms a highly active complex with Zn(II).
    Tamamura H, Otaka A, Murakami T, Ibuka T, Sakano K, Waki M, Matsumoto A, Yamamoto N, Fujii N.
    Biochem Biophys Res Commun; 1996 Dec 13; 229(2):648-52. PubMed ID: 8954952
    [Abstract] [Full Text] [Related]

  • 10. Structure-activity relationships of an anti-HIV peptide, T22.
    Tamamura H, Murakami T, Masuda M, Otaka A, Takada W, Ibuka T, Nakashima H, Waki M, Matsumoto A, Yamamoto N.
    Biochem Biophys Res Commun; 1994 Dec 30; 205(3):1729-35. PubMed ID: 7811258
    [Abstract] [Full Text] [Related]

  • 11. [A synthetic peptide "T22" as anti-HIV agents].
    Nakashima H, Murakami T.
    Nihon Rinsho; 1993 Sep 30; 51 Suppl():146-52. PubMed ID: 8271378
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance.
    Tamamura H, Kuroda M, Masuda M, Otaka A, Funakoshi S, Nakashima H, Yamamoto N, Waki M, Matsumoto A, Lancelin JM.
    Biochim Biophys Acta; 1993 May 13; 1163(2):209-16. PubMed ID: 8490053
    [Abstract] [Full Text] [Related]

  • 14. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
    Xu Y, Tamamura H, Arakaki R, Nakashima H, Zhang X, Fujii N, Uchiyama T, Hattori T.
    AIDS Res Hum Retroviruses; 1999 Mar 20; 15(5):419-27. PubMed ID: 10195751
    [Abstract] [Full Text] [Related]

  • 15. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II).
    Masuda M, Nakashima H, Ueda T, Naba H, Ikoma R, Otaka A, Terakawa Y, Tamamura H, Ibuka T, Murakami T.
    Biochem Biophys Res Commun; 1992 Dec 15; 189(2):845-50. PubMed ID: 1472056
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
    Jansen RW, Schols D, Pauwels R, De Clercq E, Meijer DK.
    Mol Pharmacol; 1993 Nov 15; 44(5):1003-7. PubMed ID: 7902528
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection.
    Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N, Nagasawa T.
    J Exp Med; 1997 Oct 20; 186(8):1389-93. PubMed ID: 9334379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.